Last reviewed · How we verify

Clinique des Céphalées de Montréal — Portfolio Competitive Intelligence Brief

Clinique des Céphalées de Montréal pipeline: 0 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Agomab Spain S.L. · 1 shared drug class
  2. Avalo Therapeutics, Inc. · 1 shared drug class
  3. Bristol-Myers Squibb · 1 shared drug class
  4. Celltrion · 1 shared drug class
  5. Centocor, Inc. · 1 shared drug class
  6. Dermira, Inc. · 1 shared drug class
  7. European Organisation for Research and Treatment of Cancer - EORTC · 1 shared drug class
  8. Gliknik Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Clinique des Céphalées de Montréal:

Cite this brief

Drug Landscape (2026). Clinique des Céphalées de Montréal — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/clinique-des-c-phal-es-de-montr-al. Accessed 2026-05-18.

Related